City Therapeutics Unveils RNAi Drug Targeting Inherited Blindness

CAMBRIDGE, MA – May 06, 2026 – A new beacon of hope has emerged for individuals affected by Stargardt disease, the most common form of inherited macular degeneration that leads to irreversible vision loss, often beginning in childhood. At the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, Cambridge-based City Therapeutics presented compelling preclinical data for its investigational therapy, CITY-RBP4, a novel drug that may represent a first-in-class treatment for a condition that currently has no approved therapies.

The announcement signals a potential turning point for a patient community long left with only supportive care. Stargardt disease, caused by mutations in the ABCA4 gene, robs young people of their central vision, typically leading to legal blindness by their mid-20s. The new data suggests City's approach could slow or even halt this devastating progression.

A Novel Strategy to Starve the Disease

The underlying pathology of Stargardt disease involves the accumulation of toxic by-products of vitamin A (retinol) in the retina, leading to the death of critical photoreceptor cells. City Therapeutics' CITY-RBP4 employs a sophisticated biological tool known as RNA interference (RNAi) to cut off the supply chain for this toxicity.

Instead of targeting the eye directly, CITY-RBP4 is designed to silence the gene responsible for producing Retinol Binding Protein 4 (RBP4) in the liver. RBP4 acts as the primary transport vehicle for vitamin A in the bloodstream. By reducing RBP4 levels, the therapy aims to lower the amount of retinol delivered to the eye, thereby preventing the formation of the toxic deposits that cause vision loss.

The preclinical data presented at ARVO provides strong support for this strategy. In studies involving non-human primates, a single 3 mg/kg dose of CITY-RBP4 successfully suppressed RBP4 and slashed circulating retinol levels by approximately 90%. The company reported that the effect was long-lasting, suggesting a convenient dosing schedule of once every three to six months for human patients.

Furthermore, in mouse models engineered to mimic Stargardt disease, a similar RNAi-based approach reduced the primary toxic by-product, A2E, to normal levels. This provides crucial evidence that the mechanism can effectively address the root cause of retinal damage.

“Reducing retinol delivery to the eye as an approach to Stargardt treatment has long been an area of interest,” said Tracy Zimmermann, Ph.D., chief scientific officer of City Therapeutics, in a statement. “We are encouraged by these early findings showing substantial reductions in both RBP4 and toxic retinoid by-products, which support the continued development of CITY-RBP4.”

Entering a Competitive Field of Hope

While City Therapeutics' announcement is a significant milestone, it enters an increasingly active and competitive landscape for Stargardt disease treatments. For years, the only recourse for patients has been supportive care, including using low-vision aids and avoiding high-dose vitamin A supplements. Now, a diverse array of therapeutic strategies is advancing through clinical trials, offering multiple avenues of hope.

Several companies are pursuing gene therapies, which aim to correct the faulty ABCA4 gene. Because the gene is too large for standard viral vectors, companies like VeonGen and SpliceBio are developing innovative dual-vector systems. Others, like Ocugen, are using a modifier gene therapy approach with its candidate, OCU410ST, which is already in a Phase 2/3 trial.

Oral small molecules also represent a major area of research. Belite Bio's Tinlarebant, which also works to reduce vitamin A accumulation, recently reported positive topline results from its pivotal Phase 3 trial, positioning it as a potential first-to-market therapy. Meanwhile, Alkeus Pharmaceuticals' ALK-001, a modified form of vitamin A, has shown it can slow lesion growth in Phase 2 trials and has received Breakthrough Therapy designation from the FDA.

Other cutting-edge approaches include Ascidian Therapeutics' RNA editing therapy, ACDN-01, which corrects the genetic message at the RNA level and has entered a Phase 1/2 trial. This diverse pipeline underscores the intense scientific and commercial interest in finally providing a meaningful treatment for Stargardt patients.

The Power and Precision of RNAi

City Therapeutics' approach leverages the power of RNAi, a technology that has matured from a Nobel Prize-winning discovery into a validated drug development platform. RNAi therapies work by harnessing a natural cellular process to silence specific genes with high precision, offering a way to target disease-causing proteins at their source. Companies like Alnylam Pharmaceuticals have successfully brought multiple RNAi drugs to market for other conditions, proving the platform's viability.

The application of RNAi to an ocular disease via systemic delivery is a testament to the platform's versatility. By targeting the liver to create a systemic effect that protects the eye, CITY-RBP4 circumvents many of the challenges associated with direct drug delivery to the back of the eye. This approach promises consistent, sustained target suppression with infrequent, subcutaneous dosing, which could significantly improve patient adherence compared to more invasive or frequent treatments.

Backed by $135 million from leading life sciences investors, City Therapeutics is poised to rapidly advance its lead candidate. The company, co-founded by pioneers in the RNAi field, plans to submit a regulatory application in mid-2026 to initiate a global Phase 1 clinical study in the second half of the year.

“STGD1 is a devastating condition with no approved treatments, and we are encouraged by the potential of CITY-RBP4 to address the underlying disease process,” commented Baisong Mei, M.D., Ph.D., the company's chief medical officer. “These preclinical data demonstrate the depth, specificity and durability of CITY-RBP4... and we look forward to continuing to explore its therapeutic promise as we enter the clinic.”

The upcoming Phase 1 trial will be a critical first step in evaluating the safety, tolerability, and activity of CITY-RBP4 in humans. For the thousands of patients and families affected by Stargardt disease, this transition from preclinical promise to clinical reality represents a vital and eagerly anticipated step forward.